A Case of m0CRPC after Hormone Therapy for Pelvic Lymph Node Metastasis in which Salvage RARP was Effective

• Published in: Hinyokika kiyo. Acta urologica Japonica Vol. 69; no. 2; pp. 59 - 62
• Main Authors: Kokubun, Hidetoshi, Kubota, Masashi, Kambe, Takanari, Mine, Yuta, Hagimoto, Hiroki, Yamaguchi, Ritsuki, Murata, Shiori, Makita, Noriyuki, Hattori, Yuto, Abe, Yohei, Tsutsumi, Naofumi, Yamasaki, Toshinari, Inoue, Koji, Kawakita, Mutsushi
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.02.2023
• Subjects: Androgen Antagonists; Androgens; Humans; Lymphatic Metastasis; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - surgery
• ISSN: 0018-1994
• DOI: 10.14989/ActaUrolJap_69_2_59

The patient was a 63-year-old man with biopsy Gleason score of 4＋5 prostate cancer with an initial prostate specific antigen level of (PSA) 51.2ng/ml. On imaging examination, extracapsular invasion, rectal invasion, and pararectal lymph node metastasis were found (cT4N1M0). After 4 years of androgen deprivation therapy, PSA decreased to 0.631ng/ml, and then increased gradually to1.2ng/ml. Computed tomographic scan showed that the primary tumor had shrunk and lymph node metastasis had disappeared; so salvage robot-assisted resection of the prostate (RARP) was performed for non-metastatic castration-resistant prostate cancer (m0CRPC). Since PSA decreased to an undetactable level, hormone therapy was terminated at 1 year. The patient remained recurrence-free for 3 years after surgery. RARP may be effective for m0CRPC, enabling discontinuation of androgen deprivation therapy.